More SAEs With Biologic Agents vs Placebo in Treatment of Psoriasis
Findings from many meta-analyses do not reflect the real-world safety of biologic agents for psoriasis.
Plaque Psoriasis
Tildrakizumab Effective for Psoriasis Regardless of Metabolic Syndrome Status
The efficacy of tildrakizumab for the treatment of psoriasis in patients with and without metabolic syndrome was assessed.
Long-Term Brodalumab Use Successful for Plaque Psoriasis
The effects of brodalumab in the treatment of plaque psoriasis may be sustained over the long term with the appropriate dose and dosing interval.
Evaluating the Safety of Adalimumab for Pediatric Plaque Psoriasis
Safety data for adalimumab therapy for plaque psoriasis in children is derived from studies in adults, which undercores the need for dedicated pediatric research.
Significant Improvements Observed With Apremilast in Mild to Moderate Plaque Psoriasis
Amgen announced positive topline results from the phase 3 study of apremilast (Otezla®), a phosphodiesterase 4 (PDE4) inhibitor, for the treatment of adults with mild to moderate plaque psoriasis.
Biologic, Immunosuppressive Therapies Not Tied to Severe Outcomes From COVID-19 Infection
A study from Italy reports severe outcomes related to the COVID-19 infection in patients with chronic plaque psoriasis receiving immunosuppressive therapies.
Ustekinumab a Safe Treatment Option for Psoriasis in Pediatric Patients
Although ustekinumab is approved for treatment in patients 12 years of age and older, this study finds that younger patients can also be safely treated with the therapy.
AAD and NPF Release Joint Guideline on New and Standard Therapies for Psoriasis
A recap of the efficacy, safety of the most common medications and recommendations to assist prescribers in initiating and managing psoriasis.
Taltz Approved for Pediatric Patients with Moderate to Severe Plaque Psoriasis
The FDA has approved the supplemental Biologics License Application (sBLA) for Taltz (ixekizumab: Lilly) injection for the treatment of pediatric patients aged ≥6 years with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Biologics Tied to Greater Reduction in Pediatric Psoriasis
Biologics seem to be associated with greater reduction in psoriasis severity scores and higher drug survival rates than methotrexate in pediatric patients treated in a real-world setting.
-
Loading...
-
Loading...
Next post in Psoriasis
